TEZSPIRE® DELIVERED HISTOLOGIC REMISSION AND SYMPTOM IMPROVEMENT IN EOSINOPHILIC ESOPHAGITIS
Amgen and AstraZeneca announced positive full results from the Phase 3 CROSSING trial of TEZSPIRE in eosinophilic esophagitis, with histologic remission achieved in 64.8% (210 mg) and 68.9% (420 mg) of patients at week 24 versus 3.5% on placebo. Improvements in dysphagia symptoms and endoscopic features were statistically significant and sustained through week 52, including total endoscopic remission in 34.4% vs. 4.1% on placebo at the 210 mg dose. TEZSPIRE is already approved for severe asthma and CRSwNP; EoE, affecting more than 470,000 people in the US, remains an investigational indication, and the safety profile was consistent with known indications.
Key figures
- Drug Name
- TEZSPIRE (tezepelumab-ekko)
- Phase Of Trial
- Phase 3
- Doses
- 210 mg and 420 mg subcutaneous every four weeks
- Patients randomized
- 368
- Histologic remission wk24 210mg
- 64.8%
- Histologic remission wk24 420mg
- 68.9%
- Histologic remission wk52 210mg
- 67.8%
- Histologic remission wk52 420mg
- 63.3%
- Histologic remission placebo wk24
- 3.5%
- Total endoscopic remission wk52 210mg
- 34.4%
- Total endoscopic remission wk52 placebo
- 4.1%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.